UTMD

Utah Medical Products, Inc. (UTMD) 10Y Growth Potential Analysis (2026)

Invetso Score: 6.4/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Growth Runway

UTMD continues to show steady profitability and cash generation, but the current TTM revenue base and valuation imply a more measured long-term growth profile than a high-growth compounder.

The company’s very strong liquidity and minimal leverage provide flexibility to fund organic expansion or opportunistic capital allocation.

Profitability

UTMD maintains strong margins, with TTM gross margin at 54.9%, EBIT margin at 33.9%, and net margin at 29.0%.

Returns remain solid, including ROE of 8.7% and ROIC of 6.8%, supporting a durable earnings engine.

Financial Strength

The balance sheet remains exceptionally strong, with a current ratio of 48.6x and essentially no debt (debt-to-equity of 0.0016x).

Cash generation is robust, with free cash flow yield of 4.9% and free cash flow conversion near 96.6% of operating cash flow.

Valuation

UTMD trades at a premium multiple for a mature business, including 22.2x earnings, 6.4x sales, and 20.2x free cash flow.

The valuation is supported by quality and balance-sheet strength, but it still leaves limited room for multiple expansion without faster growth.

Capital Allocation

Capital allocation appears shareholder-friendly, with a dividend yield of 1.7% and modest payout ratio of 37.6%.

With very low leverage and ample cash, management has flexibility to continue dividends while preserving optionality for reinvestment or buybacks.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Utah Medical Products, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →